Keywords: کاهش دهنده چربی خون; Peripheral arterial disease; Lipid-lowering therapy; LDL cholesterol; Lipid targets; Statin adherence;
مقالات ISI کاهش دهنده چربی خون (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: کاهش دهنده چربی خون; Ezetimibe; PCSK9 inhibitors; Lipid-lowering therapy; Atherosclerosis; Plaque regression; ACS; acute coronary syndrome; ASCVD; atherosclerotic cardiovascular disease; CuVIC; Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction Afte
Keywords: کاهش دهنده چربی خون; Cardiovascular disease; Familial hypercholesterolemia; Statins; Residual cardiovascular risk; Lipid-lowering therapy; Risk factors;
Keywords: کاهش دهنده چربی خون; Cardiovascular diseases; Diabetes mellitus; LDL-C; Lipid-lowering therapy; LDL-C goal attainment; Real-world evidence; Germany;
Keywords: کاهش دهنده چربی خون; Atherosclerosis; Plaque stabilisation; Non-invasive assessment of atherosclerosis; Lipid-lowering therapy; Aterosclerosis; Estabilización de la placa; Técnicas no invasivas de imagen vascular; Hipolipemiantes;
Keywords: کاهش دهنده چربی خون; Familial hypercholesterolaemia; Cardiovascular disease; Heterozygous familial hypercholesterolaemia; Cascade screening; Lipid-lowering therapy;
Keywords: کاهش دهنده چربی خون; Familial hypercholesterolemia; Lipid-lowering therapy; Coronary heart disease; Cardiac catheterization;
Keywords: کاهش دهنده چربی خون; Cardiovascular disease; Epidemiology; Guidelines; LDL-C; Lipid-lowering therapy; Risk; Morbidity; Mortality;
Keywords: کاهش دهنده چربی خون; Cardiovascular disease; Mortality; Lifetime risk; Lipid-lowering therapy;
Keywords: کاهش دهنده چربی خون; Lipid-lowering therapy; Statins; Compliance; RegistryTerapêutica de redução de lípidos; Estatinas; Adesão terapêutica; Registo
Keywords: کاهش دهنده چربی خون; Lipid-lowering therapy; Statins; Compliance; RegistryTerapêutica de redução de lípidos; Estatinas; Adesão terapêutica; Registo
Keywords: کاهش دهنده چربی خون; Cardiovascular disease; Guidelines; Blood lipids; Lipid-lowering therapy; Australia
Keywords: کاهش دهنده چربی خون; cholesterol; cost-effectiveness; cost-utility; lipid-lowering therapy;
Low-density lipoprotein cholesterol target achievement in patients surviving an acute coronary syndrome in Hong Kong and Taiwan - findings from the Dyslipidemia International Study II
Keywords: کاهش دهنده چربی خون; cholesterol; lipid-lowering therapy; acute coronary syndrome; statins; dyslipidemia;
Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors
Keywords: کاهش دهنده چربی خون; Type 2 diabetes; Low-density lipoprotein cholesterol; Cardiovascular risk; Lipid-lowering therapy;
Atherosclerosis in cholesterol-fed rabbits and in homozygous and heterozygous LDL receptor-deficient humans
Keywords: کاهش دهنده چربی خون; Aortic root; Homozygous familial hypercholesterolaemia; Heterozygous familial hypercholesterolaemia; Lipid-lowering therapy;
Polimorfismos de los genes APOA1 y APOB y concentraciones de sus apolipoproteÃnas como biomarcadores de riesgo en el sÃndrome coronario agudo: relación con la efectividad del tratamiento hipolipemiante
Keywords: کاهش دهنده چربی خون; SÃndrome coronario agudo; Riesgo aterogénico; ApolipoproteÃna AI; ApolipoproteÃna B; Tratamiento de reducción de lÃpidos; Acute coronary syndrome; Atherogenic risk; Apolipoprotein AI; Apolipoprotein B; Lipid-lowering therapy;
APOA1 and APOB polymorphisms and apolipoprotein concentrations as biomarkers of risk in acute coronary syndrome: Relationship with lipid-lowering therapy effectiveness
Keywords: کاهش دهنده چربی خون; Acute coronary syndrome; Atherogenic risk; Apolipoprotein AI; Apolipoprotein B; Lipid-lowering therapy; SÃndrome coronario agudo; Riesgo aterogénico; ApolipoproteÃna AI; ApolipoproteÃna B; Tratamiento de reducción de lÃpidos;
Treatment goal attainment in children with familial hypercholesterolemia: A cohort study of 302 children in Norway
Keywords: کاهش دهنده چربی خون; Familial hypercholesterolemia; Children; LDL cholesterol; Lipid-lowering therapy; Genetic testing;
Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis
Keywords: کاهش دهنده چربی خون; Low-LDL; PCSK9 inhibitors; Ezetimibe; Lipid-lowering therapy; Low-LDL safety;
Clinical Genetic Testing for Familial Hypercholesterolemia
Keywords: کاهش دهنده چربی خون; cascade testing; consensus statement; familial hypercholesterolemia; genetic counseling; genetic testing; ACMG; American College of Medical Genetics and Genomics; APOB; apolipoprotein B; CAD; coronary artery disease; DLCNC; Dutch Lipid Clinic Network Diag
Use of guideline-recommended management in established coronary heart disease in the observational DYSIS II study
Keywords: کاهش دهنده چربی خون; ACS; Acute coronary syndrome; CHD; coronary heart disease; CKD; chronic kidney disease; DYSIS II; Dyslipidemia International Study II; eGFR; estimated glomerular filtration rate; HDL-C; high-density lipoprotein cholesterol; LDL-C; low-density lipoprotein
¿Es posible la regresión de la placa aterosclerótica?
Keywords: کاهش دهنده چربی خون; Aterosclerosis; Estabilización de la placa; Técnicas no invasivas de imagen vascular; Hipolipemiantes; Atherosclerosis; Plaque stabilization; Non-invasive assessment of atherosclerosis; Lipid-lowering therapy;
Consecución de objetivos terapéuticos de colesterol LDL en niños y adolescentes con hipercolesterolemia familiar. Registro longitudinal SAFEHEART
Keywords: کاهش دهنده چربی خون; Hipercolesterolemia familiar; Objetivos de colesterol unido a lipoproteÃnas de baja densidad; Terapia hipolipemiante; Enfermedad cardiovascular; Niños; Adolescentes; Estatinas; Familial hypercholesterolemia; Low-density lipoprotein cholesterol goals; Li
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial
Keywords: کاهش دهنده چربی خون; Alirocumab; Diabetes; Insulin; LDL-C; ODYSSEY; PCSK9; AE; adverse event; Apo; apolipoprotein; ASCVD; atherosclerotic cardiovascular disease; CHD; coronary heart disease; CV; cardiovascular; CVD; cardiovascular disease; DM; diabetes mellitus; HDL-C; high-d
Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study
Keywords: کاهش دهنده چربی خون; Hyperlipidaemia; Statins; LDL-cholesterol; Coronary heart disease; Target; Hyperlipidémie; Statines; LDL-cholestérol; Maladie coronaire; Objectif; ACS; acute coronary syndrome; CHD; coronary heart disease; DYSIS; Dyslipidemia International Study; EAS; E
Proprotein convertase subtilisin/kexin 9Â inhibition in patients with familial hypercholesterolemia: Initial clinical experience
Keywords: کاهش دهنده چربی خون; Cardiovascular disease; Familial hypercholesterolemia; PCSK9 inhibitors; Lipid-lowering therapy; Side effects; Injection site reaction;
Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up
Keywords: کاهش دهنده چربی خون; cardiovascular disease; LDL-receptor mutations; lipid-lowering therapy; low-density lipoprotein cholesterol; apo; apolipoprotein; ASCVD; atherosclerotic cardiovascular disease; CI; confidence interval; DNA; deoxyribonucleic acid; FH; heterozygous familial
Familial hypercholesterolemia/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity
Keywords: کاهش دهنده چربی خون; Autosomal dominant; Autosomal recessive; Familial hypercholesterolemia; Genotype; Heterozygote; Heterozygous; Homozygote; Homozygous; LDL-C level; Lipid-lowering therapy; Monogenic; Phenotype; Statins;
Estatinas en pacientes con síndrome coronario agudo. Más allá de las lipoproteínas de baja densidad
Keywords: کاهش دهنده چربی خون; Síndrome coronario agudo; Estatinas; Efectos pleotrópicos; cLDL; Tratamiento hipolipemianteAcute coronary syndrome; Statins; Pleiotropic effects; Low-density lipoprotein cholesterol; Lipid-lowering therapy
Clinician-Patient Risk Discussion for Atherosclerotic Cardiovascular Disease Prevention: Importance to Implementation of the 2013 ACC/AHA Guidelines
Keywords: کاهش دهنده چربی خون; cerebrovascular disease; coronary heart disease; lipid-lowering therapy; myocardial infarction; risk estimation; shared decision making; ACC; American College of Cardiology; AHA; American Heart Association; app; application; ASCVD; atherosclerotic cardio
Cholesterol Metabolism in CKD
Keywords: کاهش دهنده چربی خون; Cholesterol transport; chronic kidney disease (CKD); atherosclerosis; high-density lipoprotein (HDL); low-density lipoprotein (LDL); inflammation; dyslipidemia; cardiovascular disease (CVD); uremic toxins; reactive oxygen species (ROS); lipid-lowering the
Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia
Keywords: کاهش دهنده چربی خون; LDLR gene; Lipid-lowering therapy; Familial hypercholesterolemia; Type of mutation;
Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: Can we do better? Analysis of results obtained during the past two decades in 1669 French subjects
Keywords: کاهش دهنده چربی خون; Familial hypercholesterolemia; Lipid-lowering therapy; Statins; LDL-cholesterol;
A four-year naturalistic prospective study of cardiometabolic disease in antipsychotic-treated patients
Keywords: کاهش دهنده چربی خون; Antipsychotics; Obesity; Diabetes; Cardiovascular risk; Metabolic syndrome; Lipid-lowering therapy;
Apolipoprotein E genotype as a most significant predictor of lipid response at lipid-lowering therapy: Mechanistic and clinical studies
Keywords: کاهش دهنده چربی خون; Apolipoprotein E; Triglyceride; Lipid-lowering therapy
Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapy
Keywords: کاهش دهنده چربی خون; Clinical trials; Legacy effect; Lipid-lowering therapy; Mortality; Niacin; Statins
Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands
Keywords: کاهش دهنده چربی خون; Familial hypercholesterolemia; LDL-c treatment goal; Lipid-lowering therapy;
Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients
Keywords: کاهش دهنده چربی خون; Atherosclerotic vascular disease; Coronary heart disease; Goal attainment; Lipid-lowering therapy; Low-density lipoprotein cholesterol
Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy : A PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22) Analysis
Keywords: کاهش دهنده چربی خون; LDL-C; lipid-lowering therapy; atorvastatin; pravastatin; outcomesACS, acute coronary syndromes; CABG, coronary artery bypass graft; CHD, coronary heart disease; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; LDL-C
Defining the metabolic syndrome: Resolving unresolved issues?
Keywords: کاهش دهنده چربی خون; Metabolic syndrome; Definitions; Cardiovascular risk; Lipid-lowering therapy
Lipid management in ischemic stroke patients
Keywords: کاهش دهنده چربی خون; Dyslipidemia; Ischemic stroke; Lipid management; Lipid-lowering therapy
Cardiovascular and Metabolic Risk Factors: How Can We Improve Outcomes in the High-Risk Patient?
Keywords: کاهش دهنده چربی خون; Atherosclerotic cardiovascular disease; Framingham risk score; Lipid-lowering therapy; Metabolic syndrome; Primary prevention; Secondary prevention
The impact of lipid-lowering treatment patterns on LDL-C reduction and goal attainment in secondary prevention in Germany
Keywords: کاهش دهنده چربی خون; Treatment patterns; Lipid-lowering therapy; Prescription persistence; Goal attainment;
Hipercolesterolemia familiar. Criterios diagnósticos y tratamientos actuales
Keywords: کاهش دهنده چربی خون; Hipercolesterolemia familiar; Criterios diagnósticos; Tratamiento hipolipemiante; Familial hypercholesterolemia; Diagnostic criteria; Lipid-lowering therapy;
¿Son necesarios los estudios angiográficos para valorar la eficacia terapéutica del tratamiento hipolipemiante?
Keywords: کاهش دهنده چربی خون; Aterosclerosis; Tratamiento hipolipemiante; Estudios de regresión; EcografÃa carotÃdea; Grosor Ãntima-media; EcografÃa intravascular; Calcio coronario; Resonancia magnética vascular; Atherosclerosis; Lipid-lowering therapy; Regression studies; Carot
Status of lipid-lowering therapy prescribedbased on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: A study of the Japan Lipid Assessment Program (J-LAP)
Keywords: کاهش دهنده چربی خون; J-LAP; hyperlipidemia; lipid-lowering therapy; guidelines; achievement rates for management goals; HMG-CoA reductase inhibitors; statins;